Publication Topic

Lancet JE, Sacks NC, Cyr PL, Chiarella MT, Louie AC, Cortes JE. VYXEOS™ (CPX-351) increases event-rree survival and time spent out of the hospital in acute myeloid leukemia patients, compared with 7+3 standard of care. Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco CA, April 2016.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246; doi: 10.1016/j.jval.2016.03.1051.

Sacks NC, Sharma A, Cyr PL, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611; doi: 10.1016/j.jval.2016.09.1523.

Katz AJ, Chia VM, Schoonen WM, Kelsh MA. 2015. Acute lymphoblastic leukemia: An assessment of international incidence, survival, and disease burden. Cancer Causes Control 26(11):1627–1642.

Suh M, Mittal L, Hirsch S, Valdes R, Bartlett C, Rohr A, Proctor D. 2015. Lung cancer risk in chromate production workers exposed to hexavalent chromium. Presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Lancet JE, Cyr PL, Sacks NC, Chiarella MT, Louie AC, Cortes JE. CPX-351 enables administration of consolidation treatment in the outpatient setting and increases the time spent out of the hospital after completion of AML treatment compared with 7+3. American Society of Hematology Annual Meeting, San Diego CA, 2015.

Erichsen R, Kelsh MA, Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Taipei, Taiwan, October 28–30, 2014.

Jensen IS, Halbert RJ, Thompson SF, Hennessy D, Pacconi S, McSweeney PA. Increased use of plerixafor in patients with multiple myeloma and non-Hodgkin’s lymphoma in the United States: A budgetary impact analysis. Abstract C14, Academy of Managed Care Pharmacy 26^th Annual Meeting & Expo, 2014.